UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Do We Really Need Aspirin Loading for STEMI?

Ye, Regina; Jneid, Hani; Alam, Mahboob; Uretsky, Barry F; Atar, Dan; Kitakaze, Masafumi; Davidson, Sean M; ... Birnbaum, Yochai; + view all (2022) Do We Really Need Aspirin Loading for STEMI? Cardiovascular Drugs and Therapy 10.1007/s10557-022-07327-x. (In press).

[thumbnail of Davidson_Aspirin for STEMI- RPS.pdf] Text
Davidson_Aspirin for STEMI- RPS.pdf
Access restricted to UCL open access staff until 17 February 2023.

Download (339kB)

Abstract

Aspirin loading (chewable or intravenous) as soon as possible after presentation is a class I recommendation by current ST elevation myocardial infarction (STEMI) guidelines. Earlier achievement of therapeutic antiplatelet effects by aspirin loading has long been considered the standard of care. However, the effects of the loading dose of aspirin (alone or in addition to a chronic maintenance oral dose) have not been studied. A large proportion of myocardial cell death occurs upon and after reperfusion (reperfusion injury). Numerous agents and interventions have been shown to limit infarct size in animal models when administered before or immediately after reperfusion. However, these interventions have predominantly failed to show significant protection in clinical studies. In the current review, we raise the hypothesis that aspirin loading may be the culprit. Data obtained from animal models consistently show that statins, ticagrelor, opiates, and ischemic postconditioning limit myocardial infarct size. In most of these studies, aspirin was not administered. However, when aspirin was administered before reperfusion (as is the case in the majority of studies enrolling STEMI patients), the protective effects of statin, ticagrelor, morphine, and ischemic postconditioning were attenuated, which can be plausibly attributable to aspirin loading. We therefore suggest studying the effects of aspirin loading before reperfusion on the infarct size limiting effects of statins, ticagrelor, morphine, and/ or postconditioning in large animal models using long reperfusion periods (at least 24 h). If indeed aspirin attenuates the protective effects, clinical trials should be conducted comparing aspirin loading to alternative antiplatelet regimens without aspirin loading in patients with STEMI undergoing primary percutaneous coronary intervention.

Type: Article
Title: Do We Really Need Aspirin Loading for STEMI?
Location: United States
DOI: 10.1007/s10557-022-07327-x
Publisher version: https://doi.org/10.1007/s10557-022-07327-x
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Pharmacology & Pharmacy, Cardiovascular System & Cardiology, Animal models, Aspirin, Humans, Infarct size, Postconditioning, Reperfusion injury, Statins, STEMI, ELEVATION MYOCARDIAL-INFARCTION, PERCUTANEOUS CORONARY INTERVENTION, ISCHEMIA-REPERFUSION INJURY, INDUCED DELAYED CARDIOPROTECTION, OPIOID RECEPTOR ACTIVATION, NITRIC-OXIDE SYNTHASE, NF-KAPPA-B, ATORVASTATIN PRETREATMENT, PLATELET INHIBITION, SIZE-REDUCTION
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Pre-clinical and Fundamental Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery.ucl.ac.uk/id/eprint/10145790
Downloads since deposit
1Download
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item